Biogen (BIIB) plunged in pre-market trading after the company said its multiple sclerosis treatment missed the primary and secondary endpoints in a Phase 2 study.
WHAT'S NEW: Biogen this morning announced results from its Phase 2 SYNERGY study evaluating opicinumab for people with relapsing forms of multiple sclerosis, or MS. The company said the drug missed the primary endpoint, which it noted was a measure evaluating improvement of physical function, disability and cognitive function. Additionally, Biogen said the study also missed the secondary endpoint, which evaluated the slowing of disability progression, as well as safety and pharmacokinetics. The company noted that evidence of a "clinical effect with a complex, unexpected dose-response," and added that the drug was generally well-tolerated and the safety profile was consistent with what had been observed in previous studies.
The SYNERGY Phase 2 study evaluated opicinumab among 418 patients with relapsing forms of MS over 72 weeks. Results are expected to be presented at future medical meetings, the company said.
WHAT'S NOTABLE: Biogen Chief Medical Officer Alfred Sandrock said that the company will continue to analyse the results of the SYNERGY study to inform the design of its next study.
PRICE ACTION: Biogen shares are down about 9% in pre-market trading following the announcement.
Comments
Log in or sign up to join the conversation.